ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 253 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $490,500 | -18.8% | 90,000 | 0.0% | 0.12% | -12.9% |
| Q2 2023 | $603,900 | -24.1% | 90,000 | 0.0% | 0.13% | -27.5% |
| Q1 2023 | $795,150 | +18.6% | 90,000 | 0.0% | 0.18% | +16.7% |
| Q4 2022 | $670,365 | +1.6% | 90,000 | 0.0% | 0.16% | +6.8% |
| Q3 2022 | $660,000 | -9.3% | 90,000 | 0.0% | 0.15% | -7.0% |
| Q2 2022 | $728,000 | -41.7% | 90,000 | 0.0% | 0.16% | -36.2% |
| Q1 2022 | $1,249,000 | -50.5% | 90,000 | 0.0% | 0.25% | -46.8% |
| Q4 2021 | $2,525,000 | -17.5% | 90,000 | 0.0% | 0.46% | -22.5% |
| Q3 2021 | $3,059,000 | -16.9% | 90,000 | 0.0% | 0.60% | -20.4% |
| Q2 2021 | $3,682,000 | +1.6% | 90,000 | 0.0% | 0.75% | -2.7% |
| Q1 2021 | $3,623,000 | -31.7% | 90,000 | 0.0% | 0.77% | -36.0% |
| Q4 2020 | $5,303,000 | +21.2% | 90,000 | 0.0% | 1.20% | +19.6% |
| Q3 2020 | $4,377,000 | +0.5% | 90,000 | 0.0% | 1.01% | +21.9% |
| Q2 2020 | $4,354,000 | +59.8% | 90,000 | -10.0% | 0.83% | +39.8% |
| Q1 2020 | $2,724,000 | – | 100,000 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 1,014,860 | $14,086,000 | 3.47% |
| Triatomic Management LP | 297,048 | $4,123,000 | 3.35% |
| Diametric Capital, LP | 265,000 | $3,678,000 | 2.03% |
| Matrix Capital Management Company, LP | 11,572,590 | $160,628,000 | 1.93% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $416,313,000 | 1.68% |
| TIGER MANAGEMENT L.L.C. | 589,311 | $8,180,000 | 1.35% |
| Aristotle Atlantic Partners, LLC | 759,412 | $10,541,000 | 0.65% |
| Casdin Capital, LLC | 1,000,000 | $13,880,000 | 0.62% |
| Pier Capital, LLC | 339,541 | $4,713,000 | 0.60% |
| Leeward Financial Partners, LLC | 68,504 | $951,000 | 0.59% |